key: cord-0694709-7whiu7b5
authors: Jang, Kristine; Khatri, Akshay; Majure, David T.
title: “COVID-19 Leading to Acute Encephalopathy in a Heart Transplant Patient”
date: 2020-06-06
journal: J Heart Lung Transplant
DOI: 10.1016/j.healun.2020.05.016
sha: d93fce81801b94d9d81175df4a85135cbe93bac2
doc_id: 694709
cord_uid: 7whiu7b5

nan

There is increasing evidence that SARS-CoV-2 impacts the neurologic system (1) (2) (3) .

However, how the immunosuppressed state modifies neurologic involvement and clinical course remains uncertain (4) . We describe a heart transplant patient who developed prolonged symptoms of encephalopathy late in COVID-19 illness.

A 67 year-old-man was admitted with fever, cough, nasal congestion, sore throat, and diarrhea 20 months following uneventful heart transplantation. He was not hypoxic. Chest CT showed bilateral multifocal peripheral ground glass opacities (GGOs). WBC count was 4720/uL with lymphocyte count of 1040/uL. Blood cultures and CMV PCR were unremarkable. C-reactive protein (CRP) was 0.55mg/dL. Nasopharyngeal PCR for SARS-CoV-2 was positive, consistent with COVID-19 illness. Immunosuppression included 500mg mycophenolate twice daily and tacrolimus with trough level of 7.6ng/mL at admission.

Mycophenolate was discontinued. Tacrolimus was maintained for goal level of 7-10ng/mL. He continued to have intermittent fevers (Figure 1 ), but was never hypoxic. Chest CT on day six showed worsening GGOs. Hydroxychloroquine was started day seven (400mg BID first day, then 200mg BID for four days). He was discharged day 9.

He was readmitted two days later with confusion, anorexia, and emesis. He was alert, oriented only to person, and was febrile. He had no prior history of delirium or encephalopathy and was on stable home dose of venlafaxine for treatment of history of depression. Exam was notable for postural and action tremor, without focal neurological deficits. CRP was increased to 10.7mg/dL with mild elevation in AST/ALT to maximum of 74 and 79U/L, respectively. Serum ammonia and thyroid stimulating hormone were normal. Serum sodium was decreased to 133meq/L (normal range 135-145 meq/L), but returned to normal by day two of readmission. Blood urea nitrogen and serum creatinine were 42mg/dL and 1.73mg/dL, respectively, unchanged from baseline. Trough tacrolimus level at readmission was 11.5ng/mL and averaged 10±1.2ng/mL during the admission.

Hydroxychloroquine was discontinued.

CT scan of the head was unremarkable. Chest CT showed minimal progression of GGOs.

Brain MRI showed mild scattered foci of peri-ventricle deep and subcortical white matter ischemia. There was no evidence of encephalitis, posterior reversible encephalopathy or leukoencephalopathy. Repeat MRI one week later was unchanged. Electroencephalogram showed mild nonspecific diffuse multifocal cerebral dysfunction with no seizure seen.

Lumbar puncture showed 1 lymphocyte, normal protein and glucose. CSF was negative for herpes simplex PCR and Cryptococcus antigen. PCR of CSF, not validated for detection of SARS-CoV-2, was negative. By day 16, CRP began to decline. Mental status slowly improved and he was discharged 13 days after readmission. Excutive function and memory remained poor but gradually returned to normal approximately 45 days after the onset of the encephalopathy.

While we were unable to demonstrate presence of SARS-CoV-2 virus in the CSF of our patient, no alternative diagnosis for his encephalopathy was found. Sepsis is unlikely to be an explanation as symptoms started after clinical stabilization and he had limited signs or symptoms of organ dysfunction. Hydroxychloroquine has been associated with neurologic changes, but symptoms persisted for more than two weeks following discontinuation(5).

The onset of encephalopathy coincided with increased markers of inflammation, most notably CRP. The impact of immunosuppression in patients with COVID-19 remains uncertain, and severity of illness in case reports has been varied (6, 7) . It is possible that immunosuppression may attenuate severity of disease by limiting the extent of cytokine 4 release, which may be the primary mediator of injury (8) ; however, a recent report suggests poor outcomes in hospitalized solid organ transplant patients (9) . The optimal degree of immunosuppression in heart transplant patients with COVID-19 remains uncertain.

COVID-19 has been associated with acute hemorrhagic necrotizing and hypoxic encephalopathy, encephalitis, delirium, and anosmia (1, (10) (11) (12) . Other β-coronaviruses, such as SARS-CoV-1 and MERS-CoV have been shown to be neurotropic and manifest with delirium(1). The ACE2 receptor (the primary source of cell entry of the virus) is expressed in both neurons and glia and could serve as a mechanism of direct viral entry into the nervous system. Alternatively, the inflammatory state itself may give rise to encephalopathy (13) and patients with acute respiratory distress syndrome have been shown to have a high rate of persistent dysexecutive syndrome similar to our patient(3); however our patient was never hypoxic or severely ill prior to onset of symptoms and symptoms persisted for many days following normalization of markers of inflammation;

Given the novel presentations of COVID-19, we believe it is important for transplant centers to consider the potential for delayed neurologic manifestations.

Disclosures: None Figure 1 

Neuroinfection may potentially contribute to pathophysiology and clinical manifestations of COVID-19

Nervous system involvement after infection with COVID-19 and other coronaviruses

Neurologic Features in Severe SARS-CoV-2 Infection

Novel Coronavirus-19 (COVID-19) in the Immunocompromised Transplant Recipient: #Flatteningthecurve

Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study

Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?

First Cases of COVID-19 in Heart Transplantation From China

COVID-19: consider cytokine storm syndromes and immunosuppression

COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter

COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Encephalitis as a clinical manifestation of COVID-19

Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms